SM 20220

Drug Profile

SM 20220

Alternative Names: SM-20220

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 08 Feb 2008 Discontinued - Preclinical for Neurological disorders (Prevention) in Japan (IV)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 11 Feb 2004 A preclinical study has been added to the Neurological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top